Infliximab
Mostrando 1-12 de 82 artigos, teses e dissertações.
-
1. THE EVALUATION OF INFLIXIMAB TROUGH LEVEL FAVORS MAINTENANCE THERAPY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
RESUMO Contexto: A doença de Crohn e a colite ulcerativa são doenças crônicas nas quais existem desregulação do sistema imune da mucosa do trato gastrointestinal. Uma das terapias usadas no tratamento dessas doenças são as medicações biológicas, entre elas o Infliximabe. A monitorização do tratamento dos pacientes com Iinfliximabe é feita por
Arquivos de Gastroenterologia. Publicado em: 2023
-
2. Infliximab for Anoperineal Lesions in Crohn’s Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
ABSTRACT Study Aim The aim of the present study was to compare in real life the characteristics of treatment with infliximab according to the presence or absence of anoperineal involvement in Crohn’s disease. Methods We performed a single-center, prospective, non-interventional study, on patients with Crohn’s disease in remission who had been treated w
Journal of Coloproctology (Rio de Janeiro). Publicado em: 2022
-
3. Indoleamine-2,3-dioxygenase-related anti-inflammatory effects of 3-aminobenzamide and infliximab in experimental colitis
SUMMARY OBJECTIVE: This study aimed to investigate the presence of indoleamine-2,3-dioxygenase and bacterial translocation after the administration of 3-aminobenzamide and infliximab in the TNBS model of rat colitis. METHODS: The study group was divided into five categories as follows: group 1: (control), group 2: colitis+saline, group 3: colitis+3-aminobe
Revista da Associação Médica Brasileira. Publicado em: 2022
-
4. Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease,
Abstract As the treatment of infectious and parasitic diseases improved, the prevalence of these conditions declined. However, with the expansion of the use of immunobiologicals, opportunistic infections have emerged, especially under atypical presentations. The present study reports the case of a patient treated with infliximab for Crohn's disease, who pres
An. Bras. Dermatol.. Publicado em: 2021-03
-
5. Infliximab-induced remission improves physical activity in patients with active Crohn's disease
RESUMO OBJETIVO: Comparar o nível de atividade física (AF), capacidade de exercício e composição corporal antes e após remissão clínica induzida por infliximabe em pacientes com doença de Crohn (DC). MÉTODOS: Neste estudo longitudinal prospectivo, foram envolvidos 44 pacientes ambulatoriais adultos com DC ativa avaliados antes e depois de 24 sema
Rev. Assoc. Med. Bras.. Publicado em: 2020-11
-
6. Spitz nevus and infliximab: association or coincidence?,
Abstract Biological therapies, including anti-TNF agents, are important in the treatment of various chronic inflammatory diseases, including psoriasis, rheumatoid arthritis or inflammatory bowel disease. The increased use of these drugs translates into an increasing awareness of its adverse effects, which include malignancy. In this paper, we describe the ca
An. Bras. Dermatol.. Publicado em: 2020-10
-
7. The production of biopharmaceuticals in Brazil: current issues
Biopharmaceuticals are gaining a growing share of the pharmaceuticals market. In recent years, the Brazilian Health Surveillance Agency (ANVISA) has approved the registration of biological drugs with domestic production. Although Brazil is in the early stages of biopharmaceutical production, governmental incentives and the investment in private companies in
Braz. J. Pharm. Sci.. Publicado em: 20/12/2019
-
8. Effects of anti-TNF-α in experimental diversion colitis
Abstract Purpose: To evaluate the effects of infliximab on the inflammation of the colonic mucosa devoid from fecal stream. Methods: Twenty-four rats were submitted to a Hartmann's procedure. They remained for 12 weeks with the fecal derivation to development of diversion colitis on excluded colorectal stump. After this period, they were divided into 3 gro
Acta Cir. Bras.. Publicado em: 13/12/2019
-
9. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up
An. Bras. Dermatol.. Publicado em: 17/10/2019
-
10. PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY
RESUMO CONTEXTO: A atividade física na vida diária e a capacidade de exercício não tem sido avaliada em pacientes com doença de Crohn. OBJETIVO: Avaliar a atividade física na vida diária, capacidade de exercício, qualidade de vida e distúrbios de humor em pacientes com doença de Crohn moderada-grave em remissão induzida pelo infliximabe, e as
Arq. Gastroenterol.. Publicado em: 14/10/2019
-
11. Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
Clinics. Publicado em: 26/09/2019
-
12. Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
Clinics. Publicado em: 26/09/2019